Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flex-a-new
- Development stage
- Unknown
- Lead developer
- Altman Health
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flex-a-new is a dietary supplement formulated as a combination of glucosamine and chondroitin sulfate. It is primarily used for the management of symptoms associated with knee osteoarthritis. Glucosamine is an amino sugar that serves as a precursor for glycosaminoglycans, which are major components of joint cartilage, while chondroitin sulfate is a sulfated glycosaminoglycan that provides resistance to compression. The supplement is intended to support joint health and modify symptoms such as pain and stiffness.
- Brand names
- Flex-a-new
- Other names
- glucosamine and chondroitin sulfate
02
Targets
NF-κBIL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Flex-a-new.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flex-a-new.